2Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth, 1999,83 : 302-320.
3Song Y, Liu QY, Vassalle M. On the antiarrhythmic actions of magnesium in singl guinea-pig ventricular myocytes. Clin Exp Pharmacol Physiol, 1996,23:830- 838.
4Smart SC, LoCurto A, el Schultz J, et al. Intracoronary amiloride prevents contractile dysfunction of postischemic "stunned'myocardium:role of hemodynamic alterations and inhibition of Na^+ /H^+ exchange and L-type Ca^2+ channels. J Am Coll Cardiol,1995,26:1365-1373.
5Herzog W,Schlossberg M, MacMurdy K, et al. Timing of magnesium therapy affects experimental infarct size. Circulation,1995, 92 : 2622-2626.
6Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the "no reflow" phenomenon. A predictor of complications and left ventrlcular remodeling in reperfused anterior wall myocardial infarction. Circulation, 1996,93 : 223-228.
7Tofukuji M,Stamler A, Li J, et al. Effects of magnesium cardioplegia on regulation of the porcine coronary circulation. J Surg Res,1997.69:233-239.
8Sugiyama A, Xue Yx, Hagihara A, et al. Characterization of magnesium sulfate as an antiarrhythmic agent. J Cardiovasc Pharmacol Ther, 1996,1 : 243-254.
9Wilkes NJ, Mallett SV, Peachey T, et al. Correction of ionized plasma magnesium during cardiopulmonary bypass reduces the risk of postoperative cardiac arrhythmia. Anesth Analg, 2002,95:828-834.
10Speziale G, Ruvolo G, Fattocuch K, et al. Arrhythmia prophylaxis after coronary artery bypass grafting : regimens of magnesium sul~ate administration. Thorac Cardiovasc Surg, 2000,48: 22-26.
二级参考文献6
1Fibrinolytic Therapy Trialists Collaborative Group. Indications for Fibrinolytic Therapy in suspected AMI: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 1994;343(2) :31
2Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet, 1992;339(8809) : 1553～1558
3ISIS-4: a randomised factorial trial assessing early oral captopril,oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4(Fourth International Study of Infarct Survival) CollaborativeGro
4Atar D,Serebruany V,Poulton J,et al. Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. J Cardiovasc Pharmacol, 1994 ;24(4): 603 -611
5Seelig MS,Elin RJ. Is there a place for magnesium in the treatment of acute myocardial infarction? Am Heart J,1996;132(2 Pt 2 Su) :471-477.
